Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria

BACKGROUND AND OBJECTIVE: In patients with mild-to-moderate COVID-19 and at high risk of progression, casirivimab/imdevimab and bamlanivimab/etesivimab were utilized in Umbria from late April to November 2021. This period was characterized by an initial prevalence of alpha (B1.1.1.7) and its progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiaroli, Elisabetta, De Socio, Giuseppe Vittorio, Gidari, Anna, Malincarne, Lisa, Benedetti, Sara, Lanzi, Alessandra, Bastianelli, Sabrina, Pierucci, Sara, Busti, Chiara, Fagotti, Benedetta, Vicenti, Ilaria, Zazzi, Maurizio, Francisci, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266464/
https://www.ncbi.nlm.nih.gov/pubmed/35865399
http://dx.doi.org/10.4084/MJHID.2022.050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266464/
https://www.ncbi.nlm.nih.gov/pubmed/35865399
http://dx.doi.org/10.4084/MJHID.2022.050

Ejemplares similares